RespireRx Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RSPI research report →
Price Chart
About the company
RespireRx Pharmaceuticals Inc. is dedicated to researching, developing, and commercializing pharmaceutical products aimed at addressing neurological and psychiatric conditions. The company operates through two primary therapeutic platforms: ResolutionRx, which investigates pharmaceutical cannabinoids, and EndeavourRx, focused on neuromodulators.
- CEO
- Arnold S. Lippa
- IPO
- 1989
- Employees
- 2
- HQ
- Glen Rock, NJ, US
Get TickerSpark's AI analysis on RSPI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $657.75K
- P/E
- -0.05
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -2.25
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 19.21%
- ROIC
- 16.88%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,579,355
- Net Income
- $-2,102,720+45.7%
- EPS
- $-0.04+10.5%
- OCF Growth
- +84.9%
- FCF Growth
- +85.0%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.61
- RSI (14)
- 57
- Avg Volume
- 30.10K
No earnings-call transcripts are available for RSPI yet.
- Free Float
- 93.4%
- Shares Outstanding
- 365.42M
- Float Shares
- 341.18M
Buy/sell ratio 2.44. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 20 | Dickason David | other | 2,000,000 |
| Sep 25, 20 | Dickason David | other | 0 |
| Sep 30, 20 | Jones Timothy L. | other | 4,409,063 |
| Sep 30, 20 | Jones Timothy L. | other | 4,409,063 |
| Sep 30, 20 | Jones Timothy L. | other | 4,409,063 |
| Sep 30, 20 | Jones Timothy L. | other | 4,409,063 |
| Sep 30, 20 | Jones Timothy L. | other | 28.218 |
| Sep 30, 20 | Jones Timothy L. | other | 28.218 |
| Sep 30, 20 | Jones Timothy L. | other | 28.218 |
| Sep 30, 20 | Jones Timothy L. | other | 28.218 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RSPI coverage
Recent articles, reports, and earnings notes.
No research on RSPI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RSPI report →Reviewing Cortex Pharmaceuticals (OTCMKTS:RSPI) & Stoke Therapeutics (NASDAQ:STOK)
defenseworld.net · Dec 22
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
globenewswire.com · Nov 20
RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement
globenewswire.com · Nov 19
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
globenewswire.com · May 29
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
globenewswire.com · Mar 20
RespireRx's key asset moves to next stage of NIH initiative
proactiveinvestors.com · Feb 13
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
globenewswire.com · Feb 13
RespireRx Pharmaceuticals strengthens board, adding new director
proactiveinvestors.com · Jan 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.